Document is current
Any future updates will be listed below
-
Authors
Spiteri, Valentina A.
Segal, Dmitri
Correa-Sáez, Alejandro https://orcid.org/0000-0001-5240-4865
Iso, Kentaro https://orcid.org/0000-0001-5417-3642
Casement, Ryan https://orcid.org/0000-0001-8075-0757
Muñoz i Ordoño, Miquel https://orcid.org/0009-0003-4391-6393
Nakasone, Mark A. https://orcid.org/0000-0002-1362-191X
Sathe, Gajanan https://orcid.org/0000-0002-6239-5365
Schätz, Caroline https://orcid.org/0000-0002-8391-8778
Peters, Hannah E.
Doward, Mark https://orcid.org/0000-0001-5765-0926
Kainacher, Lisa
Cowan, Angus D. https://orcid.org/0000-0002-9702-7319
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
- License Information
-
More Information
Article History
Received: 4 August 2025
Accepted: 14 April 2026
First Online: 12 May 2026
Competing interests
: A.C. is a scientific founder and shareholder of Amphista Therapeutics, a company that is developing TPD therapeutic platforms. A.C. is on the scientific advisory board of ProtOS Bio and TRIMTECH Therapeutics. The A.C. laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. G.E.W. is a scientific founder and shareholder of Proxygen and Solgate and is on the scientific advisory board of Proxygen. He holds equity in Cellgate Therapeutics. He also holds equity in Nexo Therapeutics and serves on their scientific advisory board. The G.E.W. lab received research funding from Pfizer. The other authors declare no competing interests.
